

**BIOCON PHARMA MALTA I LIMITED**  
**BALANCE SHEET AS AT MARCH 31, 2022**

(All amounts in EUR, except share data and per share data, unless otherwise stated)

	<u>Note</u>	<u>March 31, 2022</u>
<b>ASSETS</b>		
<b>Current assets</b>		
Financial assets		
(i) Cash and cash equivalents	3	1,00,000
(i) Other financial assets	3	1,28,244
Other current assets	5	1,757
<b>Total current assets</b>		<b>2,30,001</b>
<b>TOTAL</b>		
		<b>2,30,001</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	4(a)	1,200
Other equity	4(b)	(9,615)
<b>Total equity</b>		<b>(8,415)</b>
<b>Non-Current liabilities</b>		
Financial liabilities		
(i) Borrowings	7	1,00,000
<b>Total Non-current liabilities</b>		<b>1,00,000</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Borrowings	3	-
(i) Trade payables	6	1,38,416
(ii) Other financial liabilities	9	-
Other current liabilities	10	-
<b>Total current liabilities</b>		<b>1,38,416</b>
<b>TOTAL</b>		
		<b>2,30,001</b>

The accompanying notes are an integral part of the financial statements.

**BIOCON PHARMA MALTA I LIMITED****STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2022****(All amounts in EUR, except share data and per share data, unless otherwise stated)**

	<u>Note</u>	<u>Period ended March'22</u>
<b>Income</b>		
Other income		-
<b>Total income</b>		<b>-</b>
<b>Expenses</b>		
Employee benefits expense	12	
Finance Cost	13	
Other expenses		9,615
<b>Total expenses</b>		<b>9,615</b>
<b>Profit/(Loss) before tax</b>		<b>(9,615)</b>
<b>Tax expenses</b>		-
<b>Total tax expense</b>		<b>-</b>
<b>Profit/(Loss) for the period</b>		<b>(9,615)</b>

The accompanying notes are an integral part of the financial statements.

**BIOCON PHARMA MALTA I LIMITED****STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED MARCH 31, 2022**

(All amounts in EUR, except share data and per share data, unless otherwise stated)

**A. Equity share capital**

	<u>March 31, 2022</u>
Opening balance	-
Changes in share capital during the period	1,200
<b>Closing balance</b>	<b><u>1,200</u></b>

**B. Other equity**

Particulars	Other equity	
	Retained earnings	Total other equity
<b>Balance as at January 25, 2021</b>	-	-
Loss for the period	(9,615)	(9,615)
Other comprehensive income	-	-
<b>Total comprehensive income for the period</b>	(9,615)	(9,615)
<b>Balance as at March 31, 2022</b>	<b>(9,615)</b>	<b>(9,615)</b>

The accompanying notes are an integral part of the financial statements.

**BIOCON PHARMA MALTA I LIMITED**  
**STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED MARCH 31, 2022**  
 (All amounts are in GBP, except share data and per share data, unless otherwise stated)

	<b>Period ended March'22</b>
<hr/>	
<b>I Cash flows from operating activities</b>	
Loss after tax	(9,615)
<u>Adjustments to reconcile profit before tax to net cash flows:</u>	
Interest expense	-
Operating profit before working capital changes	<u>(9,615)</u>
<b>Movements in working capital</b>	
(Increase)/Decrease in loans and advances and other assets	(1,28,801)
Increase/ (decrease) in trade payable, other liabilities and provisions	<u>1,38,416</u>
<b>Cash generated from operations</b>	-
Direct taxes paid, net	-
<b>Net cash flow from operating activities</b>	<u>-</u>
<b>II Cash flows from investing activities</b>	
Purchase of tangible assets	-
<b>Net cash flow from / (used) in investing activities</b>	<u>-</u>
<b>III Cash flows from financing activities</b>	
Proceeds from long-term borrowings	1,00,000
Repayment of long-term borrowings	-
Proceeds from issuance of share capital	-
Interest paid	-
<b>Net cash flow used in financing activities</b>	<u>1,00,000</u>
<b>IV Net increase in cash and cash equivalents (I + II + III)</b>	<b>1,00,000</b>
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-
VI Cash and cash equivalents at the beginning of the period	-
<b>VIII Cash and cash equivalents at the end of the period (IV + V + VI)</b>	<u><b>1,00,000</b></u>
<b>Reconciliation of cash and cash equivalents as per statement of cash flow</b>	
<b>Cash and cash equivalents</b>	
Balances with banks - on current accounts	1,00,000
Cash on hand	-
	<u>1,00,000</u>
Book overdraft	-
<b>Total cash and cash equivalents [refer note 8]</b>	<u><b>1,00,000</b></u>

The accompanying notes are an integral part of the financial statements.

**BIOCON PHARMA MALTA I LIMITED**  
**Notes to the financial statements for the period ended March 31, 2022**  
**(All amounts in EUR, except share data and per share data, unless otherwise stated)**

**March 31, 2022**

**3. Other financial assets**

**(a) Current**

Others	1,28,244
	<u>1,28,244</u>

**5. Other assets**

**(a) Current**

Advances to suppliers	-
Prepayments	-
Balances with statutory / government authorities	1,757
	<u>1,757</u>

**4(a). Equity share capital**

**Authorised**

5,000,000 ordinary shares of EUR 1 per share	<u>50,00,000</u>
--	------------------

**Issued, subscribed and fully paid-up**

1,200 ordinary shares of EUR 1 per share	<u>1,200</u>
--	--------------

**4(b). Other equity**

**Retained earnings**

The amount that can be distributed by the Company as dividends to its equity shareholders.

**March 31, 2022**

**7. Borrowings**

**Non-Current**

Loan from Associate Companies	1,00,000
	<u>1,00,000</u>

**6. Trade payables**

Trade payables	1,38,416
	<u>1,38,416</u>

**9. Other financial liabilities**

**Current**

Interest Accrued	-
	<u>-</u>

**10. Other liabilities**

**Current**

Statutory taxes and dues payable	-
	<u>-</u>

**Period ended March'22**

**7. Other expenses**

Professional charges	9,770
Professional charges R&D	-
Miscellaneous Expense	-155
	<u>9,615</u>